Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial.

Svensson M, Schmidt EB, Jørgensen KA, Christensen JH; OPACH Study Group.

Clin J Am Soc Nephrol. 2006 Jul;1(4):780-6. Epub 2006 Jun 14.

2.

n-3 fatty acids and the risk of sudden cardiac death. Emphasis on heart rate variability.

Christensen JH.

Dan Med Bull. 2003 Nov;50(4):347-67. Review.

PMID:
14694851
4.

n-3 fatty acids and revascularization procedures.

Arnesen H.

Lipids. 2001;36 Suppl:S103-6. Review.

PMID:
11837981
5.
6.

n-3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored.

Calder PC.

Clin Sci (Lond). 2004 Jul;107(1):1-11. Review.

PMID:
15132735
7.

Secondary prevention of coronary artery disease with omega-3 fatty acids.

Jacobson TA.

Am J Cardiol. 2006 Aug 21;98(4A):61i-70i. Epub 2006 May 30. Review.

PMID:
16919518
8.

Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.

Arca M, Gaspardone A.

Drugs. 2007;67 Suppl 1:29-42. Review.

PMID:
17910519
9.

Omega-3 polyunsatured fatty acids role in postmyocardial infarction therapy.

Imazio M, Forno D, Quaglia C, Trinchero R.

Panminerva Med. 2003 Jun;45(2):99-107. Review.

PMID:
12855934
10.

Polyunsaturated fatty acids and cardiovascular disease.

Calzolari I, Fumagalli S, Marchionni N, Di Bari M.

Curr Pharm Des. 2009;15(36):4094-102. Review.

PMID:
20041811
11.

Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin.

Bybee KA, Lee JH, O'Keefe JH.

Curr Med Res Opin. 2008 Apr;24(4):1217-29. doi: 10.1185/030079908X292001 . Epub 2008 Mar 20. Review.

PMID:
18358084
12.

n-3 PUFAs and cardiovascular disease prevention.

Manerba A, Vizzardi E, Metra M, Dei Cas L.

Future Cardiol. 2010 May;6(3):343-50. doi: 10.2217/fca.10.19. Review.

PMID:
20462340
13.

[The role of omega-3 fatty acids from fish in prevention of cardiovascular diseases].

Reiner E, Tedeschi-Reiner E, Stajminger G.

Lijec Vjesn. 2007 Oct-Nov;129(10-11):350-5. Review. Croatian.

PMID:
18257336
14.
15.

Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.

Plosker GL, Lyseng-Williamson KA.

Pharmacoeconomics. 2007;25(12):1031-53. Review.

PMID:
18047388
16.
17.

Prevention of cardiovascular diseases and highly concentrated n-3 polyunsaturated fatty acids (PUFAs).

Weber HS, Selimi D, Huber G.

Herz. 2006 Dec;31 Suppl 3:24-30. Review.

PMID:
17575803
18.

The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases.

Simopoulos AP.

Exp Biol Med (Maywood). 2008 Jun;233(6):674-88. doi: 10.3181/0711-MR-311. Epub 2008 Apr 11. Review.

PMID:
18408140
19.

Omega-3 polyunsaturated acids and cardiovascular disease: notable ethnic differences or unfulfilled promise?

Patel JV, Tracey I, Hughes EA, Lip GY.

J Thromb Haemost. 2010 Oct;8(10):2095-104. doi: 10.1111/j.1538-7836.2010.03956.x. Review.

20.

Highly purified omega-3 polyunsaturated fatty acids in clinical development.

Vik H.

Herz. 2006 Dec;31 Suppl 3:83-95. Review.

PMID:
17575810
Items per page

Supplemental Content

Write to the Help Desk